Frédéric V.
- Country
- France
- Department
- Oncologie
Research Overview
- Evaluation of Reduced Duration of Adjuvant Endocrine Therapy with Exemestane, Anastrozole, and Letrozole in Postmenopausal Women with Low-Risk HR+ HER2- Breast Cancer
- Adjuvant Pembrolizumab and Paclitaxel Versus Surveillance in Early Triple-Negative Breast Cancer with High Stromal Tumor-Infiltrating Lymphocytes
- Phase 3 Randomized Study of Sacituzumab Govitecan and Pembrolizumab Versus Physician's Choice and Pembrolizumab in PD-L1 Positive Metastatic Triple-Negative Breast Cancer
Data & Insights
Has run more than one trial at 122 of 371 partner sites.
Specializations
Hormone-Sensitive Breast Cancer
This investigator specializes in developing therapeutic approaches for hormone-sensitive breast cancer, with particular focus on optimizing aromatase inhibitor therapy durations for postmenopausal women with localized disease.
- Luminal A breast cancer management
- Low-risk metastatic recurrence assessment
- Hormone therapy optimization
Triple-Negative Breast Cancer
The investigator conducts research in triple-negative breast cancer treatment, exploring innovative combinations of immunotherapy and chemotherapy, with specific attention to tumor-infiltrating lymphocytes.
- Early-stage TNBC management
- Pembrolizumab-based therapy
- Sacituzumab govitecan applications
HER2-Positive/Low Disease
The investigator focuses on advancing treatment options for HER2-positive and HER2-low breast cancer, evaluating novel therapeutic agents including tucatinib and trastuzumab deruxtecan.
- Advanced/metastatic HER2+ disease
- HER2-low hormone receptor positive cancer
- Targeted therapy development
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.